3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
10
Endocrine
2
NET
1
Genitourinary
1
Conditions
Neuroendocrine Tumors
1
Neoplasms
1
Interventions
lutetium Lu 177 dotatate
28
Magnetic Resonance Spectroscopy
15
Everolimus
10
pembrolizumab
9
Specimen Handling
9
cabozantinib
7
Nivolumab
7
Lutetium-177
6
surufatinib
5
lenvatinib
5
Octreotide
5
177Lu-octreotide, DOTA(0)-Tyr(3)-
5
lanreotide
4
gallium Ga 68 dotatate
4
amino-acid, glucose, and electrolyte solution
4
X-Rays
4
Lutetium
4
Ipilimumab
4
Injections
4
Fluorodeoxyglucose F18
4
Capecitabine
4
olaparib
3
copper dotatate CU-64
3
atezolizumab
3
Temozolomide
3
Cyclophosphamide
3
Carboplatin
3
pasireotide
2
fludarabine phosphate
2
fludarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
AMG 757
×
NET
×
1 year
×
Clear all
NCT06502977
2026-04-15
DeLLphi-307
Amgen
Phase 2
Active not recruiting
32 enrolled
9 charts